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Abstract
Introduction: Various biomarkers have been reported in recent literature regarding imaging abnormalities in different types
of dementia. These biomarkers have helped to significantly improve early detection and also differentiation of various
dementia syndromes. In this study, we systematically applied whole-brain and region-of-interest (ROI) based support vector
machine classification separately and on combined information from different imaging modalities to improve the detection
and differentiation of different types of dementia.
Methods: Patients with clinically diagnosed Alzheimer’s disease (AD: n = 21), with frontotemporal lobar degeneration (FTLD:
n = 14) and control subjects (n = 13) underwent both [F18]fluorodeoxyglucose positron emission tomography (FDG-PET)
scanning and magnetic resonance imaging (MRI), together with clinical and behavioral assessment. FDG-PET and MRI data
were commonly processed to get a precise overlap of all regions in both modalities. Support vector machine classification
was applied with varying parameters separately for both modalities and to combined information obtained from MR and
FDG-PET images. ROIs were extracted from comprehensive systematic and quantitative meta-analyses investigating both
disorders.
Results: Using single-modality whole-brain and ROI information FDG-PET provided highest accuracy rates for both,
detection and differentiation of AD and FTLD compared to structural information from MRI. The ROI-based multimodal
classification, combining FDG-PET and MRI information, was highly superior to the unimodal approach and to the whole-
brain pattern classification. With this method, accuracy rate of up to 92% for the differentiation of the three groups and an
accuracy of 94% for the differentiation of AD and FTLD patients was obtained.
Conclusion: Accuracy rate obtained using combined information from both imaging modalities is the highest reported up
to now for differentiation of both types of dementia. Our results indicate a substantial gain in accuracy using combined
FDG-PET and MRI information and suggest the incorporation of such approaches to clinical diagnosis and to differential
diagnostic procedures of neurodegenerative disorders.
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Introduction
In recent research, various biomarkers have been reported to
differentiate between early stages of dementia and healthy control
subjects or between different types of neurodegenerative disorders,
suggesting an integration of these would improve diagnostic
accuracy of dementia [1]–[9].
For the detection of dementia, accuracy rates significantly above
90% have recently been reported using univariate and multivar-
iate statistical approaches in magnetic resonance imaging (MRI)
and [F18]fluorodeoxyglucose positron emission tomography
(FDG-PET) [1],[10]–[14]. However, the differentiation of the
two most common types of dementia, namely Alzheimer’s disease
(AD) and frontotemporal lobar degeneration (FTLD), is still
problematic. For this differentiation, accuracy rates ranging
between 84 and 89% are still in need of improvement, especially
due to a substantially lower sensitivity compared with specificity of
actual methods [10],[12],[15]. Nevertheless, the use of biomarkers
has significantly helped to improve diagnostic accuracy compared
with diagnoses based solely on clinical and neuropsychological
evaluation [16],[17]. For these reasons, recent studies have
suggested to incorporate imaging findings into criteria for
diagnosis of dementia [17],[18].
For AD patients imaging studies have shown reduced glucose
consumption mainly in parietotemporal and posterior cingulate
cortices [9],[20],[21] and structural changes in the hippocampus
and entorhinal area relative to healthy controls [9],[21],[22]. In
FTLD patients, atrophy and reduced metabolic rate for glucose
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have been reported to be predominately located in the medial
thalamus, amygdala and in frontotemporal and anterior cingulate
cortices [4],[8],[20],[21],[23].
For multivariate differentiation of different types of dementia
support vector machine classification (SVM) is used based on
whole-brain voxel information [10] or most frequently on ROI
values [6],[12]–[13],[24]–[26]. A major problem of the ROI-
based approach is the limited generalizability of the trained
classifier, because the ROIs are selected based on features showing
a between-group differentiation in the same groups in a univariate
analysis. Although ROIs selected with this method provide a good
discrimination between groups used in these specific studies, they
might show significantly reduced discrimination power when
applied to new data sets. This could be the case if the selected
regions just detect differences between groups, which are not
necessarily attributed to the specific neurodegenerative disorder.
Furthermore, AD and FTLD patients have been shown to develop
a differential regional pattern of glucose hypometabolism and
atrophy [21],[27]. However, the previously proposed approaches
only used single modality information for the classification
algorithms loosing this way the differential information which
various biomarkers might provide for a better detection and
differentiation of dementia syndromes.
Here, we apply SVM as the most frequently used multivariate
approach to evaluate its contribution for detection and differen-
tiation of dementia in multimodal imaging. To increase the
validity of our method we apply SVM classification on data
extracted from ROIs based on disorder-specific metabolic
reductions and atrophy reported in comprehensive meta-analyses
investigating AD and FTLD. This method allows a better
generalization of our classification algorithms to other clinical
centers and ensures that only disorder-specific changes are used for
SVM based discrimination. We hypothesize that common use of
different imaging modalities might substantially improve early
detection and differentiation of dementia.
Methods
Ethics Statement
The research protocol was approved by the Ethics Committee
of the University of Leipzig, and was in accordance with the latest
version of the Declaration of Helsinki. Informed consent was
obtained from all subjects.
Subjects
We analyzed FDG-PET and T1-weighted MRI data of 21
patients (Table 1) with an early stage of probable AD, 14 patients
with an early stage of FTLD and 13 control subjects. Patients were
recruited from the Day Clinic of Cognitive Neurology at the
University of Leipzig. Probable AD was diagnosed according to
NINCDS-ADRDA criteria [28]. Although all AD subjects also
fulfilled the revised NINCDS-ADRDA criteria suggested by
Dubois et al. [17] the fulfillment of the original McKhann criteria
was sufficient for the inclusion into the study. Diagnosis of FTLD
was based on criteria suggested by Neary et al. [29]. The control
group included subjects who visited the Day Clinic with subjective
cognitive complaints, which were not objectively confirmed by a
comprehensive neuropsychological and clinical evaluation. FDG-
PET and MRI for these subjects was conducted for diagnostic
reasons within the clinical assessment. This control group was
chosen because, in clinical practice, it is crucial to discriminate
between these subjects showing a normal age-related decrease in
cognitive performance and patients with an early stage of
dementia. Patients were excluded if structural imaging revealed
lesions due to stroke, traumatic head injury, brain tumor or
inflammatory diseases.
Data acquisition
MRI data. For each subject, a high-resolution T1-weighted
MRI scan was obtained, consisting of 128 sagittal slices adjusted to
AC-PC line and a with slice thickness of 1.5 mm and pixel size of
161 mm2. MRI was performed on two different 3T scanners
(MedSpec 30/100, Bruker Biospin, Ettlingen Germany and
Magnetom Trio, Siemens, Erlangen, Germany) using two
different T1-weighted sequences (MDEFT or MP-RAGE with
TR=1300 ms, TI = 650 ms, TE=3.93 ms or TE=10 ms; FOV
25625 cm2; matrix = 2566256 voxels). On the MedSpec
scanner, only the MDEFT-sequence and on the Magnetom Trio
scanner, either MDEFT or MP-RAGE sequences were used. The
distribution of scanner types and sequences used to obtain the
MRI data was random across subjects and did not differ
significantly in its distribution between the groups nor for
scanner type nor for sequence.
PET data. Each subject also underwent FDG-PET imaging
either a few a weeks before or after the MRI scan. All PET data
were acquired on a Siemens ECAT EXACT HR+ scanner (CTI/
Siemens, Knoxville, TN, USA) under a standard resting condition
in 2-dimensional (2D) mode. The 2D acquisition mode was used
because it allows a better quantification of the PET data due to
lower scatter radiation. Sixty-three slices were simultaneously
collected with an axial resolution of 5 mm full width at half
maximum (FWHM) and in-plane resolution of 4.6 mm. After
correction for attenuation, scatter, decay and scanner-specific
dead-time, images were reconstructed by filtered back-projection
using a Hann-filter of 4.9 mm FWHM. The 63 transaxial slices
obtained had a matrix of 1286128 voxels with an edge length of
2.45 mm.
Image processing and statistical analysis
The procedure described below has been specifically designed
for this study, aiming at a most accurate co-processing of FDG-
PET and MRI data to obtain a more precise between subject
anatomical overlap (Figure 1). All image-processing steps were
carried out using the SPM5 software package (Statistical
Parametric Mapping software: http://www.fil.ion.ucl.ac.uk/
spm/) implemented in Matlab 7.7 (MathWorks Inc., Sherborn,
MA). SVM classification was conducted with the LIBSVM
software [30] using the Matlab interface.
MR images. The MR images were first interpolated to get an
isotropic resolution of 16161 mm3. The resultant MR images
Table 1. Subject group characteristics.
Controls AD FTLD
ANOVA
(df,F,P)
Number 13 21 14 –
Male/Female 7/6 9/12 7/7 –
Age (years) 53.966.0 61.166.7 60.866.4 2, 5.76, 0.006
CDR (score) 0.2360.26 0.7160.25 0.8260.42 2, 13.93, 0.000
MMSE (score) n.a. 23.263.9 24.464.2 –
Education (years) 12.363.1 10.763.1 11.663.8 2,1.02,0.368
Mean 6 standard deviation. AD Alzheimer’s disease, ANOVA analysis of
variance, CDR Clinical Dementia Rating Scale, FTLD frontotemporal lobar
degeneration, MMSE Mini Mental State Examination, n.a. not available.
doi:10.1371/journal.pone.0018111.t001
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were coregistered on their respective FDG-PET images and bias
corrected for inhomogeneity artifacts using the Unified
Segmentation Approach described in detail by Ashburner and
Friston [31]. This specific method performs a better coregistration
of images from different modalities and allows a more accurate
segmentation due to the bias correction. A further reason to use
this approach was that the straightforward coregistration
implemented in the PVElab software described later sometimes
failed. We used this software for automatic partial volume
correction of the FDG-PET images. The coregistered MR
images were processed using the DARTEL (Diffeomorphic
Anatomical Registration Through Exponentiated Lie algebra)
approach [32] to enable a more accurate spatial normalization.
This approach registers all gray matter (GM) and white matter
(WM) images to an averaged-size template created from all
subjects used in this study and modulates the images to preserve
the total amount of signal from each region in the images.
Subsequently, the images were smoothed using a Gaussian kernel
of 12 mm FWHM. This smoothing factor, although higher then
usual MR kernels, was selected based on extensive tests, because it
allows the optimal coevaluation with lower resolution FDG-PET
images.
FDG-PET data. Within the common registration with MRI
data using the Unified Segmentation Approach described above,
PET images were interpolated to the same voxel size as the MR
images, namely 16161 mm3. This processing does not introduce
any additional noise into the PET images. However, in our
experience, it substantially improves the subsequent partial volume
effect (PVE) correction of voxels representing GM intensities using
the modified Mu¨ller-Ga¨rtner method [33],[34]. Due to the
interpolation, they are exactly overlaid with the MR tissue class
images of the same subject obtained from the segmentation step in
the PVE approach. Thus, the within-voxel correction is done only
for those voxels directly overlaying the GM structures in the MR
images. Instead of smoothing the MR data to the resolution of
PET data and thus loosing the exact quantitative and qualitative
information of GM distribution, which is usually done in the PVE
correction, the interpolation of FDG-PET preserves this
information. This allows a more accurate correction of atrophy
effects onto glucose utilization. The subsequent PVE correction
including all image processing steps was done by using the
automatic algorithm implemented in the PVElab software package
[35]. Because the modified Mu¨ller-Ga¨rtner method sets all WM
voxel values to the mean WM intensity value, these regions do not
contain any further valuable regional information after the PVE
correction. For this reason, all voxels belonging to WM were
masked using the ImCalc function in the SPM5 software package
by filtering this specific intensity in the whole image. After the PVE
correction, the DARTEL flow fields calculated from the MR
images were applied to their respective PET images to obtain an
anatomically exact overlap between GM and PET images of all
subjects with modulation to preserve the total amount of signal
from each region. In the same way as the MR data, the PET data
were smoothed by a Gaussian kernel of 12 mm FWHM. Finally,
the FDG-PET data were intensity normalized using cerebellar
ROIs to account for individual differences in global PET
measures. This region has been shown to be least affected in
mild to moderate stages of AD [36]. Additionally, normalization to
Figure 1. Schematic representation of the procedure for FDG-PET and MRI data handling and processing steps. FDG-PET
[F18]fluorodeoxyglucose positron emission tomography, MRI magnetic resonance imaging, MNI Montreal Neurological Institute, PVE partial volume
effect correction.
doi:10.1371/journal.pone.0018111.g001
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this region improves the statistical discrimination between
dementia patients and control subjects in comparison to other
regions reported in the literature [37]–[39].
Masking. The MR and PET images obtained as described
above were masked to avoid contamination by misclassified voxels.
Voxels lying between WM and ventricular cerebrospinal fluid tend
to be misclassified as GM voxels due to their similar intensity. The
mask was obtained after extensive testing by excluding all voxels in
the first and the last template created by the DARTEL approach
with a probability of below 0.2 for belonging to GM and including
only the voxels that exceed this threshold in both templates. This
mask was applied twice: firstly prior to smoothing to avoid
misclassification, and secondly, after the smoothing to avoid big
edge effects. WM images were exclusively masked using the same
mask to avoid overlaps between GM and WM voxels due to
smoothing. The masked images were used for the subsequent
SVM analysis of the data.
ROI extraction. ROI coordinates (Table 2) were extracted
from two comprehensive, systematic and quantitative meta-
analyses investigating biomarkers of AD and FTLD in MR and
FDG-PET images. The meta-analyses included a total number of
1618 patients (AD/FTLD: 1351/267) and 1448 healthy control
subjects (1097/351) [8],[9]. These meta-analyses extracted the
prototypical networks of AD and FTLD by applying what is
currently the most sophisticated and best-validated of coordinate-
based voxel-wise meta-analyses, anatomical likelihood estimate. In
the FTLD meta-analyses [8] only coordinates which are common
to all subgroups of FTLD patients were used. In total, 10 regions
from MRI and 6 regions from FDG-PET were used from the
FTLD meta-analysis. From AD meta-analysis, 6 regions were used
from both, MRI and FDG-PET. The AD meta-analysis also
identified one additional region in the fornix which was
differentiating between early-onset AD patients (age,65 years)
and control subjects but not between late-onset AD patients and
control subjects. This region was not included into the ROI-based
classification to avoid a discrimination bias towards early-onset
AD patients. Although unequal numbers of ROIs were used from
both imaging modalities, this number is also a highly important
information as it also provides a measurement for the amount of
changes present in a specific modality. Because the coordinates in
both meta-analyses were reported in the Talairach space, they
were transformed to MNI space according to a formula proposed
by Matthew Brett (published on the Internet: http://www.mrccbu.
cam.ac.uk/Imaging/Common/mnispace.shtml). DARTEL prepro-
cessed data are registered to an averaged size template created from
all subjects in this study. To transform these data to the MNI space we
normalized them to an a priori MNI template in SPM by using affine-
only spatial normalization. Due to the affine-only transformation, our
images still differed in shape from theMNI template, so some reported
coordinates were slightly outside of the anatomic regions in our
imaging data. In this case, the center coordinates for the ROIs were
moved slightly towards the closest point of the corresponding
anatomical region reported in the meta-analyses. ROIs were selected
using the 3D fill tool in the MRIcron software package (http://www.
sph.sc.edu/comd/rorden/mricron). Separate ROImasks were created
for MR and FDG-PET images based on the origin of the peak values
reported in the meta-analyses and using all regions reported for AD
and FTLD in a single mask for each modality. Each ROI was
restricted to a sphere with a radius of 5 mm around the reported
coordinate (Figure 2). Additionally, to increase the signal-to-noise ratio,
all zero voxels and edge voxels with an intensity deviation of 13
intensity units in the MRIcron 3D fill tool were excluded from the
ROI. The edge voxel restriction excludes all voxels at the edge of the
smoothed GM structures within the sphere. These voxels carry much
less information due to their further distance from theGM structures in
the unsmoothed data and so decrease the signal-to-noise ratio in the
corresponding ROI.
SVM. Multivariate pattern classification, as described in
Klo¨ppel et al. [10], was performed with a linear kernel by
identifying a separating hyperplane that maximizes the distance
Table 2. Coordinates of ROIs used for SVM classification.
FTLD vs. Controls
FDG-PET BA Lat x y z
Pregenual anterior cingulate gyrus 24/32 L 25 34 21
Lentiform nucleus; Caudate head L 220 3 23
Medial thalamus L 22 2196
Anterior insula 15/16 L 247 10 27
Anterior medial frontal cortex 10 R 1 54 0
Amygdala R 25 22 225
MRI BA Lat x y z
Anterior medial frontal cortex 9 L 25 49 25
Pregenual anterior cingulate gyrus 24/32 L 25 34 21
Inferior frontal gyrus, pars opercularis 44 L 254 11 20
Lentiform nucleus; Caudate head L 220 3 23
Anterior insula 15/16 L 247 10 27
Subcallosal/septal area 25 L 22 10 210
Amygdala R 25 22 225
Amygdala; Ento-and perirhinal cortex L 226 25 225
Temporal pole 38 L 229 11 243
Temporal pole 38 L 247 8 244
AD vs. Controls
FDG-PET BA Lat x y z
Angular gyrus 39 L 238 26837
Angular gyrus 39 R 43 26833
Posterior superior temporal sulcus 21/22
Anterior medial frontal cortex 9/10 R 1 31 31
Pregenual anterior cingulate gyrus 32
Inferior precuneus 31 R 1 23627
Dorsal posterior cingulate cortex 23
Posterior superior temporal sulcus 21/22 L 251 26123
Middle inferior temporal sulcus 20/21 R 59 231223
MRI BA Lat x y z
Posterior insula 13 L 238 22515
Medial thalamus L 25 2133
Hippocampal body/tail R 31 23826
Middle temporal gyrus/superior temporal
sulcus
21/22 L 263 22125
Amygdala, anterior hippocampal formation,
uncus, (trans-) entorhinal area
28/34 R 25 28 218
Amygdala, anterior hippocampal formation,
uncus, (trans-) entorhinal area
28/34 L 226 28 218
Coordinates are in MNI space (L left, R right). AD Alzheimer’s disease, BA
Brodmann area, FDG-PET [18F]fluorodeoxyglucose positron emission
tomography, MRI magnetic resonance imaging, ROI region-of-interest, SVM
support vector machine.
doi:10.1371/journal.pone.0018111.t002
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between different clinical groups based on whole-brain or ROIs
information. The cross-validation of the trained SVM was
performed by using the leave-one-out method. This procedure
iteratively leaves out the information of each subject and trains the
model on the remaining subjects for subsequent class assignation
of the person that was not included in the training procedure. This
validation method enables the generalization of the trained SVM
to data that have never been presented to the SVM algorithms
previously. The reported accuracy is the percentage of subjects
correctly assigned to the clinical diagnosis. Usually SVM
classification is performed without smoothing of the data,
because single voxels are assumed to contain information, for
example, for prediction of future action based on functional MR
images. However, in neurodegenerative disorders single voxels are
unlikely to contain generalizable information due to a limited
across-subject registration of MR and FDG-PET images.
Although SVM classification based on unsmoothed data has
been shown to differentiate reasonably between different groups
(Klo¨ppel et al., 2007), an additional smoothing should make this
approach more reliable and generalizable to new data. To control
for the effect of smoothing we ran the same whole-brain
classification twice for GM, PET and for integration of GM and
PET in the same vector with and without smoothing.
We performed the whole-brain SVM classification using GM,
WM or FDG-PET images separately and by combining
information from different modalities. For the SVM classification,
all data of a subject are transformed into a vector, with
information of an additional modality simply attached by
extending the vector. Additionally, we repeated the whole-brain
SVM classification by adding MR to FDG-PET information
combining both modalities in a single image. ROI-based SVM
classification was performed on data extracted from smoothed
images separately for GM and FDG-PET images and also by
integrating information from both modalities in a single vector. In
order to reduce the number of voxels in the ROI-based
classification, only nonzero voxels were included in the vector.
This was done because otherwise the whole-brain SVM
classification is a highly memory-consuming approach. To ensure
that our classification results were not based on factors randomly
discriminating between groups, we reran the whole-brain and
ROI-based classification for comparison 30 times by randomly
assigning all subjects to the three groups independently from the
clinical diagnosis and calculating the classification accuracy by
using the leave-one-out procedure described above.
Statistical analysis. Group comparisons for age, education
and CDR (Clinical Dementia Rating Scale) [40] were performed
by conducting ANOVAs (analyses of variance). If an ANOVA
revealed a significant between-group effect, a Bonferroni t-test was
calculated with a significance threshold of p,05 (corrected for
multiple comparisons, two-tailed). MMSE (Mini Mental State
Examination) [41], was only present for 20 patients with AD and
11 patients with FTLD. MMSE scores of these two groups were
compared to each other using an independent samples t-test.
Group differences regarding sex were evaluated using a chi-square
test for independent samples. The statistical analysis was
performed with the commercial software package SPSS 17.0
(http://www.spss.com/statistics/).
Results
Clinical characteristics
The chi-square test for independent samples did not reveal any
statistical differences in sex between the groups [x2(2)= 0.42;
p=0.809]. The three groups did not differ in education (Table 1).
CDR scores differed significantly in the three groups. The post-hoc
test revealed no differences in the mean CDR scores between both
groups of dementia patients [t(33) =0.94;p=0.977]. As expected,
both early AD [t(32) =5.36;p,0.001] and early FTLD
[t(25) =4.35;p,0.001] had significantly higher CDR scores com-
pared to the control subjects. MMSE scores also did not differ
between both groups of dementia patients indicating a similar severity
of dementia syndrome [t(29) =281;p=0.95]. The ANOVA also
revealed a significant group difference in age. The two groups of
dementia patients did not differ significantly in age
[t(33) =0.16;p=1.0]. There was a minor but significant difference
between AD patients and controls [t(32) =3.18;p=008] and FTLD
patients and controls [t(25) =2.86; p=024].
SVM – Whole-brain analysis
Multivariate classification of the data using SVM at the whole-
brain level revealed the best discrimination accuracy for all three
groups using FDG-PET, with 81% (chance level 33%), in comparison
to GM and WM information, with lowest accuracy using WM
information on its own (Table 3). The combination of metabolism
and GM values in a single image revealed a similar accuracy for
differentiation of the three groups, with higher accuracy for
differentiation between both types of dementia, however, with
slightly lower discrimination between dementia patients and control
subjects.Whole-brain SVM classification for the three groups without
smoothing revealed lower accuracy rates in all classifications in
comparison to differentiation based on smoothed images. The
accuracy increase due to smoothing ranged between 2 (GM) and 6%
(FDG-PET). Figure 3 displays regions that were most influential in
making binary classification between the AD, FTLD and control
subjects based on smoothed whole-brain information.
SVM – ROI analysis
Accuracy based on ROIs from both meta-analyses using only
GM information was substantially lower for differentiation
between AD and FTLD patients in comparison with whole-brain
classification. However, it was comparable to the whole-brain
Figure 2. Regions of interest extracted from gray matter (left)
and FDG-PET (right) data for AD and FTLD patients and used
for support vector machine classification projected onto a
glass brain (top) and onto an axial slice (bottom). AD Alzheimer’s
disease, FDG-PET [F18]fluorodeoxyglucose positron emission tomogra-
phy, FTLD frontotemporal lobar degeneration, GM gray matter, ROIs
regions of interest.
doi:10.1371/journal.pone.0018111.g002
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approach in differentiating between patients with both types of
dementia and control subjects. ROIs extracted from FDG-PET
data showed slightly lower discrimination accuracy compared to
whole-brain information. The best accuracy rates of all SVM
classifications were obtained using combined information extract-
ed from FDG-PET and GM data. This approach resulted in a
classification accuracy of 92% for the differentiation of all three
groups and an accuracy rate of 94% for differentiation between
AD and FTLD patients. Sensitivity of this ROI-based classification
ranged between 85.7% for FTLD and 100% for AD and
specificity of 100% for discrimination of both types of dementia
from control subjects (Table 4).
The classification accuracy in the 30 trials randomly assigning
all subjects to the three groups resulted in a mean accuracy rate of
3467.7% (mean 6 standard deviation), ranging between 21 and
52% for the ROI-based SVM classification, and 33.768.2%
ranging between 12 and 50% for the whole-brain classification.
Discussion
In this study we performed a multimodal comparison and
discrimination of dementia patients using FDG-PET and MRI. To
enable a more accurate coevaluation of both imaging modalities,
we developed a new preprocessing algorithm. This algorithm was
designed to enable an accurate anatomical registration of both
modalities. All processing steps were performed as far as possible
simultaneously by applying the same deformations and prepro-
cessing parameters to both modalities of the same subject. This
procedure resulted in an accurate anatomical overlap of both
imaging modalities and in an accurate between-subject registra-
tion, with both images having the same voxel size and
approximately the same effective smoothness.
SVM
SVM classification is a very promising tool for detection and
differentiation of different dementia syndromes, as has been shown
by previous studies [10],[12],[13],[24]. It not only captures
univariate relationships of a single voxel across all subjects but is
also able to detect multivariate relationships over a large group of
information, as, for example, between different structures and
modalities in the brain. Furthermore, this tool provides an easy
way to use this information for classifying imaging data of new
subjects to a specific condition.
Here, we systematically compared different information pro-
vided by FDG-PET and MRI to enable the most accurate
detection and differentiation of dementia. The diagnosis was based
on comprehensive clinical and neuropsychological testing. Al-
though the data are not histopathologically confirmed to be sure of
assigning them to the correct condition, generally higher
conformity with the clinical diagnosis should also result in more
accurate classification of histopathologically validated data.
The whole-brain SVM classification provided the most accurate
classification using only FDG-PET information. GM and WM
based classification accuracy was lower for all comparisons
indicating a lower sensitivity for detection of dementia-relevant
information. Nonetheless, classification based on GM, WM and
FDG-PET separately or combining them revealed a discrimina-
tion accuracy which was above chance level for the correct
categorization of the three groups. All classification results
substantially exceeded the best classification accuracy obtained
by randomly assigning all subjects to different groups. Addition-
ally, smoothing of the data improved the classification accuracy in
both imaging modalities as expected.
However, in whole-brain classification noise is introduced by
using a great deal of information for classification that does not
differentiate between the groups. Recent comprehensive meta-
analyses identified the ‘‘prototypical’’ networks for both disorders
in both modalities using VBM [8],[9]. The involved regions have
been shown to be affected in AD and FTLD patients most
consistently in all studies investigating these disorders. By using this
information, we ruled out the possibility that our classification
results are dependent to our group of patients. Although this
Table 3. Accuracy rates for whole-brain and ROI-based SVM classification for FDG-PET and MRI.
AD, FTLD and Controls AD vs FTLD AD vs Controls FTLD vs Controls
GM
whole-brain
72.9% 80.0% 88.2% 77.8%
WM
whole-brain
66.7% 74.3% 79.4% 77.8%
FDG-PET
whole-brain
81.3% 82.9% 94.1% 92.6%
GM/ FDG-PET
whole-brain
79.2% 82.9% 94.1% 88.9%
GM/WM/FDG-PET
whole-brain
77.1% 82.9% 91.2% 85.2%
GM + FDG-PET
whole-brain
81.3% 88.6% 91.2% 88.9%
GM
ROIs
56.3% 60.0% 82.4% 85.2%
FDG-PET
ROIs
75.0% 80.0% 94.1% 85.2%
GM/FDG-PET
ROIs
91.7% 94.3% 100.0% 92.6%
Accuracy represents the percentage of subjects correctly assigned to the correct condition. AD Alzheimer’s disease, FDG-PET [18F]fluorodeoxyglucose positron emission
tomography, FTLD frontotemporal lobar degeneration, GM gray matter, MRI magnetic resonance imaging, ROI region-of-interest, SVM support vector machine, WM
white matter.
doi:10.1371/journal.pone.0018111.t003
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method provides lower accuracy rates for GM or FDG-PET
information on their own, it shows a significantly higher
discrimination rate by combining both information modalities
into a single vector. This ROI-based discrimination is superior to
whole-brain classification with the highest accuracy gain for the
differentiation of both types of dementia, which, with 94%, is the
highest differentiation rate reported up to now. Accordingly, we
suggest this method as a diagnostic standard for the classification
of dementia syndromes.
Nonetheless, some limitations should be considered regarding
the results of the present study. First of all, the number of subjects
used for classification is too low to allow a generalizable conclusion
for patients from other clinical centers. This is especially a problem
because the accuracy of the clinical diagnosis for specific dementia
syndromes, which was used here for validation, strongly varies
between different clinical centers. Therefore, in a future work this
approach should be validated using a larger and more general-
izable dataset like the data provided by the Alzheimer’s disease
Neuroimaging Initiative (ADNI: www.adni-info.org). A further
limitation of the present work is the significantly younger age of
the control group in comparison to the patient cohort. However,
this aspect might only have contributed to the discrimination
between dementia patients and control subjects but not to the high
classification accuracy of AD and FTLD patients as these were
very similar in their age range. If age contributed to the
classification accuracy there should be lower classification
accuracy for young dementia patients and older control subjects
as they did not differ in age. For comparison of both types of
dementia patients and control subjects the classification accuracy
did not differ for younger and older dementia patients although
half of the patients were in the same age range as the control
group. In AD group all patients were classified correctly. In FTLD
group one younger and one older patient were misclassified.
Independently of age, all control subjects were classified correctly
for both comparisons. These results indicate that the slight mean
age differences is not the decisive factor for the high discrimination
accuracy using combined information from FDG-PET and MRI.
Furthermore, if age still slightly contributed to the high
discrimination of dementia patients and control subjects this
contribution was also present in all other single modality and
multimodal whole-brain and ROI-based SVM classifications
applied in this study. Therefore, age cannot account for increased
differentiation accuracies when combined ROI information from
FDG-PET and MRI are used for differentiation of dementia
patients and control subjects.
Another point is that subjects in the control group in our study
reported subjective cognitive complaints which might have limited
the interpretation of the results of our study. However, only
subjects were included whose cognitive complaints were not
confirmed by comprehensive neuropsychological evaluation. The
CDR is a semi-structural interview and is highly dependent on the
subjectively perceived memory impairment which resulted in a
CDR score of 0.5 for these control subjects in our study. In recent
literature it has been shown that the CDR stage of 0.5 has a poor
discriminative value for healthy control subjects and subjects with
Mild Cognitive Impairment (MCI) [42],[43]. Meguro et al. [42]
have shown that about 30% of a normal population older then 65
got a CDR score of 0.5 while the prevalence of MCI in the same
population was only about 5% which suggests that CDR score of
0.5 is not a good indicator of MCI. Due to the absence of any
objective cognitive impairment in all neuropsychological tests for
all subjects included in the control group in our study this group of
subjects can be regarded as cognitively unimpaired.
Conclusion and perspectives
In our study, we investigated the advantages of SVM
classification using combined information from FDG-PET and
MRI to improve detection and differentiation of dementia.
Table 4. Differentiation rates for combined region-of-interest
information from FDG-PET and MRI.
Accuracy Sensitivity Specificity
AD vs FTLD 94.3% 95.2%* 92.9%
AD vs Controls 100.0% 100.0% 100.0%
FTLD vs Controls 92.6% 85.7% 100.0%
*Considering a correctly identified AD as a true positive. AD Alzheimer’s disease,
FDG-PET [18F]fluorodeoxyglucose positron emission tomography, FTLD
frontotemporal lobar degeneration, MRI magnetic resonance imaging.
doi:10.1371/journal.pone.0018111.t004
Figure 3. Weights of voxels most relevant for classification of
both groups of patients and control subjects in FDG-PET and
MRI after SVM training. Weights are relative, and have no applicable
units. AD and FTLD vs Controls: Blue and light blue indicate decreased
gray matter intensity (upper row) or reduced metabolic rate (lower row)
that increase the likelihood of classification into a dementia group. Red
and yellow indicate the opposite. AD vs FTLD: Blue and light blue
indicate decreased gray matter intensity (upper row) or reduced
metabolic rate (lower row) that increase the likelihood of classification
into the AD group. Red and yellow indicate the opposite. Regions with
bright colors (yellow and light blue) have a higher importance for
separation than regions with dark colors (blue and red). AD Alzheimer’s
disease, FTLD frontotemporal lobar degeneration. MRI magnetic
resonance imaging, PET positron emission tomography.
doi:10.1371/journal.pone.0018111.g003
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Furthermore, based on affected regions reported in previous
studies, investigating Alzheimer’s disease and frontotemporal lobar
degeneration with univariate approaches and summarized in two
meta-analyses, we applied linear support vector machine classifi-
cation algorithm using information from both imaging modalities.
Combining region-of-interest information from FDG-PET and
MRI resulted in a substantial gain in accuracy compared to whole-
brain and to single modality classification for both detection and
differentiation of Alzheimer’s disease and frontotemporal lobar
degeneration. Our results indicate that integration and combina-
tion of results from different imaging modalities might provide a
new way to improve the diagnostic accuracy of these dementia
disorders.
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